ANDA 202994, held by Novast Labs. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 202994 (Larin 24 Fe), held by Novast Labs, was first approved by FDA on Feb 18, 2015, with 4 approved supplements and 0 published complete response letters.
Microgestin 24 Fe is a progestin/estrogen COC indicated for use by women to prevent pregnancy. The efficacy of Microgestin 24 Fe in women with a body mass index (BMI) of >35 kg/m 2 has not been evaluated. ( 1, 8.8 )
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 18, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Larin 24 Fe0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jun 16, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 3, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 3, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 18, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters